Follow the formulation, route, study model, and jurisdiction—not just the name. These profiles explain human-use context while keeping catalogue materials distinct from approved medicines.
Evidence at a glance: Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
CHECKED 2026-09-15
BPC-157
A synthetic 15-amino-acid peptide with extensive animal literature, sparse and methodologically weak human evidence, and no verified approved medicine in the Canadian or U.S. sources reviewed.
A common name for an acetylated seven-amino-acid fragment of thymosin beta-4; it is not full-length thymosin beta-4, and human findings for the full molecule do not transfer to TB-500.
A copper(II) complex of the tripeptide glycyl-histidyl-lysine, supported mainly by cell and animal tissue-remodelling work and a very small topical human literature.
A modified GLP-1 analogue with approved, formulation-specific medicines and large randomized human trials—evidence that does not establish the identity or suitability of an unrelated catalogue vial.
A synthetic ghrelin-receptor agonist and growth-hormone secretagogue studied in people mainly for postoperative gastrointestinal recovery, without demonstrated efficacy in the pivotal published trial.
A synthetic Ala-Glu-Asp-Gly tetrapeptide, also called Epitalon, with small biomarker studies and cell/animal findings that do not establish sleep, longevity, or anti-aging benefits in people.
Tesamorelin is a synthetic growth-hormone-releasing factor analogue. Salt, vial strength, excipients, and delivery system matter. Labeled-product trials support the specific approved indication; the reviewed records do not support general weight-loss, anti-aging, or performance claims.
NAD+ is a nucleotide-derived redox coenzyme, not a peptide. Direct NAD+, precursors, and related vitamin forms are not interchangeable. A 2025 single-centre randomized study evaluated a short intravenous course in ischemic cardiomyopathy; a later retrospective commercial-setting pilot assessed tolerability. Neither establishes broad wellness or longevity benefit.
MOTS-c is described as a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region. The reviewed sources did not identify a completed human administration study establishing safety or benefit.
5-Amino-1MQ is a small-molecule nicotinamide N-methyltransferase inhibitor, not a peptide; 1MQ is part of its name. No controlled human administration evidence was identified in the source set reviewed for this profile.
Bremelanotide is a cyclic melanocortin-receptor agonist developed from melanotan-II research; formulation and device are part of the medicine identity. The approved label summarizes placebo-controlled evidence in the defined population; results cannot be generalized to men, postmenopausal women, or other claims.
Melanotan II is a cyclic alpha-MSH analogue with activity at multiple melanocortin receptors; it is distinct from afamelanotide and bremelanotide products. A 1996 phase-I pilot enrolled three men and reported pigmentation plus nausea, fatigue, yawning, and erections. This sample is far too small for broad efficacy or safety conclusions.
Long R3 IGF-I is an IGF-I analogue engineered for reduced binding to IGF-binding proteins; it is not ordinary recombinant human IGF-1. No adequate controlled human administration study was identified for this analogue in the reviewed source set.
Kisspeptins are a peptide family derived from KISS1. Kisspeptin-10 and kisspeptin-54 are distinct fragments, so an unresolved 'Kiss 10' label cannot borrow every family result. Small and moderate studies show reproductive-hormone responses and investigate oocyte maturation, reproductive disorders, and behavioral questions, usually with explicitly defined kisspeptin-10 or -54.
Tirzepatide is a GIP- and GLP-1-receptor agonist. Approved delivery systems, concentrations, excipients, and labeling are not interchangeable with a research vial. Large product-development programs support specific branded uses; ongoing studies do not turn every metabolic claim into an approved indication.
Semax is described as a synthetic ACTH-fragment-derived heptapeptide; exact formulation and jurisdiction are essential to interpreting regional reports. Older Russian-language controlled reports describe stroke populations, but accessible methods, blinding, formulations, and independent replication are limited.
Selank is a synthetic heptapeptide related to a tuftsin fragment; free peptide and acetate should not be assumed equivalent. A Russian-language randomized report evaluated generalized anxiety disorder and neurasthenia, but the accessible evidence base is limited and lacks broad independent replication.
Elamipretide is a mitochondria-targeting tetrapeptide associated with cardiolipin binding. The SS-31 catalogue label does not establish the approved product formulation. A very small randomized crossover trial in Barth syndrome did not meet its randomized primary endpoints; its extension and later evidence informed accelerated approval based on an intermediate clinical endpoint.
Retatrutide is an investigational agonist at GIP, GLP-1, and glucagon receptors. Randomized phase 2 trials reported metabolic effects and frequent gastrointestinal adverse events. A peer-reviewed phase 3 type 2 diabetes trial was published in 2026; topline announcements should be distinguished from peer-reviewed trial reports.
Cagrilintide is a long-acting amylin analogue under clinical development. A multinational phase 2 dose-finding trial randomized 706 participants to cagrilintide doses, 99 to liraglutide, and 101 to placebo and reported weight-loss and tolerability outcomes.
The commercial label Melanotan I is commonly associated with afamelanotide, a synthetic alpha-MSH analogue, but catalogue-material equivalence is not verified. The labeled evidence comes from three randomized implant trials in 244 adults with EPP, not general tanning or an injectable vial.
AOD-9604 is a synthetic analogue based on a C-terminal region of human growth hormone, not full-length growth hormone. The reviewed source set did not provide a convincing peer-reviewed randomized human efficacy publication.
Original CJC-1295 is a long-acting GHRH analogue using a drug-affinity-complex strategy. It should not be confused with short-acting modified GRF (1-29). Two small randomized ascending-dose studies in healthy adults reported sustained GH and IGF-1 increases; biomarker changes did not establish a therapeutic outcome.
Modified GRF (1-29) refers to short GHRH analogues with substitutions intended to resist degradation. The commercial phrase 'CJC-1295 without DAC' is imprecise and does not make it original long-acting CJC-1295. Human studies of GHRH(1-29) and related analogues demonstrate acute GH biomarker responses, not broad clinical outcomes.
Sermorelin is an amidated 29-amino-acid GHRH fragment; acetate and delivery formulation remain part of product identity. Small physiology studies report acute GH responses. Historical therapeutic evidence was tied to Geref and a narrow pediatric population.
GHRP-2 is a synthetic ghrelin-receptor agonist and growth-hormone secretagogue with unnatural amino-acid features. An eight-person volunteer study measured acute GH responses; critically ill studies also exist but cannot establish wellness, body-composition, or performance benefits.
GHRP-6 is a synthetic ghrelin-receptor agonist and growth-hormone secretagogue. Small acute human physiology studies show hormone and metabolic responses but do not establish therapeutic benefit.
Thymosin alpha-1 is a 28-amino-acid peptide also known as thymalfasin; branded approvals reported outside North America do not validate an unspecified material. A 2025 multicentre double-blind phase 3 trial in 1,106 adults with sepsis found no clear reduction in 28-day all-cause mortality. Older, smaller studies in other diseases are not interchangeable.
KPV is the tripeptide Lys-Pro-Val, a C-terminal fragment associated with alpha-MSH biology. No human administration study establishing safety or benefit was identified in the reviewed source set.
DSIP is a nonapeptide historically called delta sleep-inducing peptide; endogenous identity and physiological role have been debated. A 16-person double-blind insomnia study found weak objective signals that could partly reflect placebo change and concluded major therapeutic benefit was unlikely.
ARA 290 (cibinetide) is an 11-amino-acid peptide modelled on erythropoietin helix B and designed not to stimulate red-cell production. Two small 28-day placebo-controlled trials in sarcoidosis- and diabetes-associated neuropathy reported mixed results; no approved use was verified in the sources reviewed.
Oxytocin is a nine-amino-acid peptide hormone; Health Canada lists marketed human oxytocin injections, and the reviewed U.S. label covers labour and postpartum use. In one paediatric autism trial, intranasal oxytocin did not differ significantly from placebo; social-memory findings come from mice.
Gonadorelin is synthetic GnRH, a decapeptide that releases LH and FSH. In Canada its human products are cancelled or dormant and marketed entries are veterinary. The only human evidence reviewed is one retrospective cohort of pulsatile GnRH ovulation induction in women with functional hypothalamic amenorrhea.
VIP is a 28-amino-acid neuropeptide; aviptadil is the name used for its synthetic form. Health Canada Drug Product Database searches found no aviptadil product, and a large randomized trial of intravenous aviptadil in critical COVID-19 found no significant improvement in day-90 outcomes.
AHK-Cu is described as the copper(II) complex of the tripeptide L-alanyl-L-histidyl-L-lysine, a different material from GHK-Cu. No human administration study was found in the sources reviewed; the only evidence identified is one ex vivo hair-follicle and cell-culture study.
Humanin is a 24-amino-acid peptide attributed to the mitochondrial MT-RNR2 gene (the reviewed record notes possible nuclear encoding), distinct from the S14G mutant. The evidence reviewed is cell-culture work and one observational plasma study; no approved use or human administration study was found.
B7-33 is a synthetic single-chain analogue of the human relaxin-2 B-chain, distinct from relaxin-2 and from serelaxin. No human administration study was identified in the sources reviewed, and no Canadian approved product was found; the evidence is rodent and cell-based.
Pinealon is a synthetic Glu-Asp-Arg tripeptide. This profile reviews one oxidative-stress cell study and one rat prenatal hyperhomocysteinemia study from one group, and two small uncontrolled or non-randomised human reports (abstracts only); other Russian-language reports were not reviewed. No approved use was found.